徐希奇;荆志成;
XU Xi-qi;JING Zhi-cheng;Thrombosis and Vascular Medicine Center,Fuwai Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;Key Laboratory of Pulmonary Vascular Medicine,Chinese Academy of Medical Sciences,State Key Laboratory of Cardiovascular Disease;

• 1:中国医学科学院北京协和医学院阜外医院血栓性疾病诊治中心
• 2:中国医学科学院肺血管医学重点实验室心血管疾病国家重点实验室

摘要(Abstract)：

第六届世界肺高血压会议对肺高血压(pulmonary hypertension,PH)的定义和诊断分类进行了修订和更新。PH的血流动力学定义维持不变,将毛细血管前性PH定义更新为:肺动脉平均压>20 mm Hg、肺动脉楔压<15 mm Hg且肺血管阻力>3 WU。诊断分类更新包括:增加急性肺血管扩张试验阳性肺动脉高压(pulmonary arterial hypertension,PAH)亚类,将甲基苯丙胺(冰毒)和达沙替尼致PAH作用由可能升级为肯定,将肺静脉闭塞病/肺毛细血管瘤病由特殊的1'更新为PAH的一个亚类,将脾切除术后和甲状腺疾病从PH诊断分类中移除等。本次PH定义和诊断分类更新将为临床实践提供重要指导意义。
The definition and clinical classification of pulmonary hypertension( PH) were updated in the6 th World Symposium on Pulmonary Hypertension( WSPH). The hemodynamic definition of PH keeps no change,but pre-capillary PH was redefined as mean pulmonary arterial pressure > 20 mm Hg,pulmonary artery wedge pressure< 15 mm Hg and pulmonary vessel resistance>3 WU. The updated clinical classification included:pulmonary arterial hypertension( PAH) with vasoreactivity was added as a subclass of PAH; in drugs and toxins induced PAH,the role of methamphetamines and dasatinib was updated from likely to definite; pulmonary venoocclusive disease/pulmonary capillary haemangiomatosis was changed from 1' to a subclass of PAH; splenectomy and thyroid diseases were withdrawn from the group 5 of PH,etc. These clinical practice updates will guide clinical practice better.

关键词(KeyWords)： 肺高血压;肺动脉高压;肺静脉闭塞病;达沙替尼;更新
pulmonary hypertension;pulmonary arterial hypertension;pulmonary veno-occlusive disease;dasatinib;update

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划(2016YFC0901502);; 中国医学科学院医学与健康科技创新工程(2016-I2M-1-002)

作者(Authors): 徐希奇;荆志成;
XU Xi-qi;JING Zhi-cheng;Thrombosis and Vascular Medicine Center,Fuwai Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;Key Laboratory of Pulmonary Vascular Medicine,Chinese Academy of Medical Sciences,State Key Laboratory of Cardiovascular Disease;

参考文献(References)：

• [1]Simonneau G,Gatzoulis MA,Adatia I,et al.Updated clinical classification of pulmonary hypertension[J].J Am Coll Cardiol,2013,62:D34-D41.
• [2]Kovacs G,Berghold A,Scheidl S,et al.Pulmonary arterial pressure during rest and exercise in healthy subjects:a systematic review[J].Eur Respir J,2009,34:888-894.
• [3]Mc Laughlin VV,Gaine SP,Howard LS,et al.Treatment goals of pulmonary hypertension[J].J Am Coll Cardiol,2013,62:D73-D81.
• [4]Kim NH,Delcroix M,Jenkins DP,et al.Chronic thromboembolic pulmonary hypertension[J].J Am Coll Cardiol,2013,62:D92-D99.
• [5]Rubin LJ,Badesch DB,Barst RJ,et al.Bosentan therapy for pulmonary arterial hypertension[J].N Engl J Med,2002,346:896-903.
• [6]GalièN,Humbert M,Vachiery JL,et al.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS):Endorsed by:Association for European Paediatric and Congenital Cardiology(AEPC),International Society for Heart and Lung Transplantation(ISHLT)[J].Eur Heart J,2016,37:67-119.
• [7]Valerio CJ,Schreiber BE,Handler CE,et al.Borderline mean pulmonary artery pressure in patients with systemic sclerosis:transpulmonary gradient predicts risk of developing pulmonary hypertension[J].Arthritis Rheum,2013,65:1074-1084.
• [8]Douschan P,Kovacs G,Avian A,et al.Mild Elevation of Pulmonary Arterial Pressure as A Predictor of Mortality[J].Am J Respir Crit Care Med,2018,197:509-516.
• [9]Taboada D,Pepke-Zaba J,Jenkins DP,et al.Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease[J].Eur Respir J,2014,44:1635-1645.
• [10]Simonneau G,Robbins IM,Beghetti M,et al.Updated clinical classification of pulmonary hypertension[J].J Am Coll Cardiol,2009,54:S43-S54.
• [11]Zamanian RT,Hedlin H,Greuenwald P,et al.Features and Outcomes of Methamphetamine Associated Pulmonary Arterial Hypertension[J].Am J Respir Crit Care Med,2018,197:788-800.
• [12]Weatherald J,Chaumais MC,Savale L,et al.Long-term outcomes of dasatinib-induced pulmonary arterial hypertension:a population-based study[J].Eur Respir J,2017,50:1700217.
• [13]Montani D,Girerd B,Ja6s X,et al.Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease:a population-based study[J].Lancet Respir Med,2017,5:125-134.
• [14]Ja6s X,Ioos V,Jardim C,et al.Splenectomy and chronic thromboembolic pulmonary hypertension[J].Thorax,2005,60:1031-1034.
• [15]Freitas CSG,Baldi BG,Jardim C,et al.Pulmonary hypertension in lymphangioleiomyomatosis:prevalence,severity and the role of carbon monoxide diffusion capacity as a screening method[J].Orphanet J Rare Dis,2017,12:74.
• [16]Richter MJ,Sommer N,Schermuly R,et al.The prognostic impact of thyroid function in pulmonary hypertension[J].J Heart Lung Transplant,2016,35:1427-1434.